Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine
Abstract Background The phased withdrawal of oral polio vaccine (OPV) and the introduction of inactivated poliovirus vaccine (IPV) is central to the polio ‘end-game’ strategy. Methods We analyzed the cost implications in Chile of a switch from the vaccination scheme consisting of a pentavalent vacci...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-04-01
|
| Series: | BMC Health Services Research |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12913-020-05115-7 |
| _version_ | 1818904234909761536 |
|---|---|
| author | Ignacio Olivera Carlos Grau Hugo Dibarboure Juan Pablo Torres Gustavo Mieres Luis Lazarov Fabián P. Alvarez Juan Guillermo López Yescas |
| author_facet | Ignacio Olivera Carlos Grau Hugo Dibarboure Juan Pablo Torres Gustavo Mieres Luis Lazarov Fabián P. Alvarez Juan Guillermo López Yescas |
| author_sort | Ignacio Olivera |
| collection | DOAJ |
| description | Abstract Background The phased withdrawal of oral polio vaccine (OPV) and the introduction of inactivated poliovirus vaccine (IPV) is central to the polio ‘end-game’ strategy. Methods We analyzed the cost implications in Chile of a switch from the vaccination scheme consisting of a pentavalent vaccine with whole-cell pertussis component (wP) plus IPV/OPV vaccines to a scheme with a hexavalent vaccine with acellular pertussis component (aP) and IPV (Hexaxim®) from a societal perspective. Cost data were collected from a variety of sources including national estimates and previous vaccine studies. All costs were expressed in 2017 prices (US$ 1.00 = $Ch 666.26). Results The overall costs associated with the vaccination scheme (4 doses of pentavalent vaccine plus 1 dose IPV and 3 doses OPV) from a societal perspective was estimated to be US$ 12.70 million, of which US$ 8.84 million were associated with the management of adverse events related to wP. In comparison, the cost associated with the 4-dose scheme with a hexavalent vaccine (based upon the PAHO reference price) was US$ 19.76 million. The cost of switching to the hexavalent vaccine would be an additional US$ 6.45 million. Overall, depending on the scenario, the costs of switching to the hexavalent scheme would range from an additional US$ 2.62 million to US$ 6.45 million compared with the current vaccination scheme. Conclusions The switch to the hexavalent vaccine schedule in Chile would lead to additional acquisition costs, which would be partially offset by improved logistics, and a reduction in adverse events associated with the current vaccines. |
| first_indexed | 2024-12-19T21:04:12Z |
| format | Article |
| id | doaj.art-a0b6f608f150404eade0898e76b6675b |
| institution | Directory Open Access Journal |
| issn | 1472-6963 |
| language | English |
| last_indexed | 2024-12-19T21:04:12Z |
| publishDate | 2020-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Health Services Research |
| spelling | doaj.art-a0b6f608f150404eade0898e76b6675b2022-12-21T20:05:42ZengBMCBMC Health Services Research1472-69632020-04-012011910.1186/s12913-020-05115-7Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccineIgnacio Olivera0Carlos Grau1Hugo Dibarboure2Juan Pablo Torres3Gustavo Mieres4Luis Lazarov5Fabián P. Alvarez6Juan Guillermo López Yescas7Centro de Investigaciones Económicas, CINVE, SaludCentro de Investigaciones Económicas, CINVE, SaludSanofi PasteurChile Departamento de Pediatría y Cirugía Infantil Oriente, Facultad de Medicina, Universidad de ChileCentro de Investigaciones Económicas, CINVE, SaludCentro de Investigaciones Económicas, CINVE, SaludSanofi PasteurSanofiAbstract Background The phased withdrawal of oral polio vaccine (OPV) and the introduction of inactivated poliovirus vaccine (IPV) is central to the polio ‘end-game’ strategy. Methods We analyzed the cost implications in Chile of a switch from the vaccination scheme consisting of a pentavalent vaccine with whole-cell pertussis component (wP) plus IPV/OPV vaccines to a scheme with a hexavalent vaccine with acellular pertussis component (aP) and IPV (Hexaxim®) from a societal perspective. Cost data were collected from a variety of sources including national estimates and previous vaccine studies. All costs were expressed in 2017 prices (US$ 1.00 = $Ch 666.26). Results The overall costs associated with the vaccination scheme (4 doses of pentavalent vaccine plus 1 dose IPV and 3 doses OPV) from a societal perspective was estimated to be US$ 12.70 million, of which US$ 8.84 million were associated with the management of adverse events related to wP. In comparison, the cost associated with the 4-dose scheme with a hexavalent vaccine (based upon the PAHO reference price) was US$ 19.76 million. The cost of switching to the hexavalent vaccine would be an additional US$ 6.45 million. Overall, depending on the scenario, the costs of switching to the hexavalent scheme would range from an additional US$ 2.62 million to US$ 6.45 million compared with the current vaccination scheme. Conclusions The switch to the hexavalent vaccine schedule in Chile would lead to additional acquisition costs, which would be partially offset by improved logistics, and a reduction in adverse events associated with the current vaccines.http://link.springer.com/article/10.1186/s12913-020-05115-7VaccinationCostPediatricPolio |
| spellingShingle | Ignacio Olivera Carlos Grau Hugo Dibarboure Juan Pablo Torres Gustavo Mieres Luis Lazarov Fabián P. Alvarez Juan Guillermo López Yescas Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine BMC Health Services Research Vaccination Cost Pediatric Polio |
| title | Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine |
| title_full | Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine |
| title_fullStr | Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine |
| title_full_unstemmed | Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine |
| title_short | Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine |
| title_sort | valuing the cost of improving chilean primary vaccination a cost minimization analysis of a hexavalent vaccine |
| topic | Vaccination Cost Pediatric Polio |
| url | http://link.springer.com/article/10.1186/s12913-020-05115-7 |
| work_keys_str_mv | AT ignacioolivera valuingthecostofimprovingchileanprimaryvaccinationacostminimizationanalysisofahexavalentvaccine AT carlosgrau valuingthecostofimprovingchileanprimaryvaccinationacostminimizationanalysisofahexavalentvaccine AT hugodibarboure valuingthecostofimprovingchileanprimaryvaccinationacostminimizationanalysisofahexavalentvaccine AT juanpablotorres valuingthecostofimprovingchileanprimaryvaccinationacostminimizationanalysisofahexavalentvaccine AT gustavomieres valuingthecostofimprovingchileanprimaryvaccinationacostminimizationanalysisofahexavalentvaccine AT luislazarov valuingthecostofimprovingchileanprimaryvaccinationacostminimizationanalysisofahexavalentvaccine AT fabianpalvarez valuingthecostofimprovingchileanprimaryvaccinationacostminimizationanalysisofahexavalentvaccine AT juanguillermolopezyescas valuingthecostofimprovingchileanprimaryvaccinationacostminimizationanalysisofahexavalentvaccine |